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Abstract: Current theraputic options for the treatment of symptomatic benign prostatic 
hyperplasia (BPH) are reviewed. Therapeutic options for mild lower urinary tract symptoms 
(LUTS), as defined by the American Urological Association, are generally treated medically. 
Moderate to severe LUTS can be treated medically or with surgical therapy. Current medical 
and surgical treatments for LUTS secondary to BPH are reviewed and evolving treatments are 
explored.
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Introduction
Benign prostatic hyperplasia (BPH) is a pathologic process that contributes to the 
development of lower urinary tract symptoms (LUTS) in men. LUTS, arising from 
lower urinary tract dysfunction, are further subdivided into obstructive (urinary 
hesitancy, straining, weak stream, terminal dribbling, prolonged voiding, incomplete 
emptying) and irritative (urinary frequency, urgency, nocturia, urge incontinence, small 
voided volumes) symptoms. Autopsy series have shown that no men younger than 
30 years of age have histologic evidence of BPH, while more than 50% of men greater 
than 60 years of age have histologic evidence of the disease.1 The prevalence reaches 
almost 90% in the ninth decade.1 While prostatic enlargement appears inevitable, it is 
believed that the LUTS and other sequelae of BPH are not just due to a mass effect, 
but also likely due to a combination of the prostatic enlargement and age-related 
detrusor dysfunction.2
Traditional management of BPH consisted of surgery or watchful waiting 
with treatment of complications if they arose. Medical therapy gained acceptance 
about two decades ago with the approval of alpha-adrenergic receptor antagonists 
and 5-alpha-reductase inhibitors for the treatment of symptomatic BPH. 
Alpha-adrenergic receptor antagonists were thought to treat the “dynamic” aspect of 
BPH by reducing sympathetically mediated tone of the bladder outlet and therefore 
decreasing resistance and improving urinary flow. 5-alpha-reductase inhibitors, on 
the other hand, were thought to treat the “static” aspect of BPH by reducing pros-
tate volume and having a similar albeit delayed effect. They have also proven to be 
beneficial in the prevention of BPH progression, as measured by prostate volume, the 
risk of developing acute urinary retention, and the risk of having BPH-related surgery.3 
The use of an alpha-adrenergic receptor antagonist and a 5-alpha-reductase inhibitor as 
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of BPH and has been validated by the Medical Therapy of 
Prostate Symptoms (MTOPS) trial.4 Anti-cholinergic agents 
and phosphodiesterase-5 inhibitors have also recently shown 
efficacy in the management of LUTS.
Surgical therapy, despite being the mainstay of treatment 
for LUTS secondary to BPH in the past, is now considered 
second line therapy and is usually reserved for patients after 
a trial of medical therapy. The goal of surgical therapy is to 
“debulk” the prostate, effectively reducing resistance to urine 
flow. Surgical therapy ranges from office-based to same day 
surgery to inpatient surgery. Minimally invasive therapy, 
including transurethral microwave therapy (TUMT) and 
transurethral needle ablation of the prostate (TUNA), can be 
performed in an office setting and result in partially relieving 
symptoms secondary to BPH. Transurethral resection of the 
prostate (TURP), transurethral incision of the prostate (TUIP), 
and laser therapies are endoscopic therapies performed in an 
operating room that result in significant relief of LUTS in 
patients with BPH. Open prostatectomy is an open operative 
procedure reserved for patients with large volume prostates 
that also results in significant relief of LUTS.
Etiology of BPH
The etiology of BPH is multifactorial and not definitively 
established. Benign Prostatic Hyperplasia refers to 
stromal and glandular epithelial hyperplasia that occurs 
in the zone of the prostate that surrounds the urethra. This 
overgrowth is dependent mainly on androgens, particularly 
dihydrotestosterone (DHT).5 5-alpha-reductase is responsible 
for the conversion of testosterone to DHT, an androgen with 
five times the potency of testosterone for the androgen receptor. 
DHT binds to androgen receptor and the complex is primarily 
responsible for stimulation of growth factors that influence 
prostate cell division and growth and therefore maintain the 
balance between cell proliferation and cell death. Elevated 
levels of DHT, along with hypothesized hormonal imbalances, 
result in BPH.2,5 The lack of prostate growth and resultant 
BPH or prostate cancer in male pseudohermaphrodites 
due to 5-alpha-reductase deficiency was first reported in 
1974.6,7 These observations were the rationale for the use of 
5-alpha-reductase inhibitors in the treatment of BPH.
Prostate smooth muscle represents a significant volume of 
the gland8 and its activity is mediated by the sympathetic nervous 
system.9 Prostate smooth muscle tension has recently been shown 
to be mediated by alpha1-adenoreceptor receptor.10 This is the 
rationale for the use of alpha-adrenergic receptor antagonists 
and more recently uroselective alpha-adrenergic receptor 
antagonists for the treatment of symptomatic BPH.
Natural history of BPH
BPH is a chronic, progressive condition that worsens with 
age. The natural history of BPH is progression in the majority 
of patients. This results in increased prostate size, worsening 
of symptoms, deterioration in urinary flow rate, increased 
risk of acute urinary retention, and increased risk of surgery 
for BPH.11 Longitudinal studies have shown an increase 
of moderate to severe urinary symptoms from 13% in the 
fifth decade to 28% in the eighth decade.12 An association 
between prostate size and urinary symptoms and flow rates 
has also been documented, with men developing diminishing 
flow rates with age.13 Men in the sixth decade have an average 
flow rate of 20 to 21 mL/sec, whereas men in the eighth decade 
have an average flow rate of 13 to 15 mL/sec.14 Men in their 
seventh decade with moderate LUTS had a 13% 10-year risk 
of developing acute urinary retention in longitudinal studies. 
Furthermore, men with prostate volumes greater than 20 mL 
and flow rate less than 12 mL/sec had a respective threefold 
and fourfold increased risk.15 Along with the risk of acute uri-
nary retention, the risk of undergoing BPH-related surgery also 
increases with age.16 Estimated prostate growth rates increased 
by 1.6% per year in a large community based study.16 Higher 
baseline prostate volume and elevated serum prostate-specific 
antigen (PSA) are associated with BPH progression.3,16,17 
This has led the AUA Practice Guidelines Committee to 
recommend a urinalysis, PSA, and completion of a validated 
symptom index in the initial evaluation of patients who seek 
medical attention due to symptomatic BPH.11
Overview of BPH therapy
Symptomatic relief is the most common reason men seek 
treatment for BPH and therefore the goal of therapy for 
BPH is usually relief of these LUTS.11 LUTS symptoms 
are generally measured by using a validated, reproducible 
index that is designed to determine disease severity and 
determine response to therapy – the American Urological 
Association’s Symptom Score (AUASS),11 also adopted as 
the International Prostate Symptom Score (IPSS). Serial 
AUASS are particularly useful in following patients as 
they are treated with various forms of therapy. It should be 
noted that AUASS alone is not a reliable indicator of LUTS 
suggestive of BPH, but is a quantitative measure of LUTS 
after the diagnosis is made. Medical therapy is the main-
stay for treatment of men suffering from mild to moderate 
LUTS. More invasive therapy is usually reserved for 
medical failures. There are, however, some clear indications 
for surgical therapy including acute urinary retention not 
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recurrent bladder stones, azotemia, recurrent urinary tract 
infections, and intractable hematuria.11
Surgical therapy for BPH has traditionally been 
electrosurgical resection of the prostate (TURP) or open 
prostatectomy. These therapies are associated with excellent, 
durable results with acceptable morbidity.11 Recent advances 
in laser prostatectomy have made this procedure comparable 
to the standard TURP, however long-term durability results 
are not available yet.18,19 Because of decreased morbidity, 
laser prostatectomy can be performed effectively in patients 
who have failed medical therapy and are considered too high 
a risk for traditional surgical therapy.20,21
Minimally invasive surgical therapy, office-based therapies 
such as transurethral needle ablation of the prostate, transurethral 
microwave therapy, or interstitial laser coagulation, result in 
significant increases in maximum urinary flow rate (Qmax) 
and significant decreases in AUASS.22 However, these types 
of therapies are associated with a significant re-treatment rate 
and their durability has not been adequately assessed.
Medical therapy
The initial form of therapy for BPH is medical, especially 
in patients with mild-moderate symptoms and no clear 
indication for surgical intervention.11 Current accepted 
medical therapy consists of alpha-adrenergic receptor 
antagonists, 5-alpha-reductase inhibitors, or a combination.
Alpha-adrenergic receptor antagonists
Alpha-adrenergic receptor antagonists are the main class 
of agents used for medical therapy of symptomatic BPH. 
Their use is based on the hypothesis that BPH arises from 
bladder-outlet obstruction and a large proportion of cellular 
volume is made up of smooth muscle, whose tension is 
mediated by alpha-adrenergic receptors.23 Four alpha-
adrenergic receptor antagonists are currently approved to 
treat LUTS by the Food and Drug Administration (FDA) 
in the USA: terazosin (Hytrin®), doxazosin (Cardura®), 
tamsulosin (Flomax®), and alfuzosin (UroXatral®).
The alpha-adrenergic receptor antagonist terazosin has 
been used for the treatment of BPH since 1992 and was 
approved for such use in 1993 by the FDA. A multicenter trial 
of terazosin demonstrated the efficacy of alpha-adrenergic 
receptor antagonists with an approximately 6-point 
improvement in AUASS and 3 mL/sec improvement in 
maximum urinary flow rate (Qmax) after 1 year of therapy.24 
Subsequent multicenter trials with doxazosin demonstrated 
similar clinical results,25,26 and the alpha-adrenergic receptor 
antagonists became the medical therapy of choice for BPH. 
Side effects of alpha-adrenergic receptor antagonist therapy 
(Table 1) can hinder compliance and consist mainly of 
dizziness, postural hypotension, asthenia, nasal congestion, 
gastrointestinal symptoms, headache, and occasionally ret-
rograde ejaculation.27 Dizziness and asthenia are the main 
reason for discontinuation of alpha-adrenergic receptor 
antagonists.
Uroselectivity, the preferential action on the prostate 
and bladder with decreased LUTS while producing 
minimal side effects, has become a primary consideration 
when choosing an alpha-adrenergic receptor antagonist.27 
Tamsulosin, an alpha 1a and 1d subtype uroselective alpha-
adrenergic receptor antagonist, was approved by the FDA in 
1997 and has similar efficacy to terazosin and doxazosin.28 
It has significantly decreased cardiovascular side effects and 
has become the alpha-blocker of choice for most urologists. 
Long-term safety and efficacy has been established for 
tamsulosin via a 4-year open label extension trial that 
evaluated patients that had at least 2 years prior experience 
with the drug.28 This study of 609 patients demonstrated that 
rapid improvements in AUA symptom index and maximum 
urinary flow rates were sustained throughout the maximum 
duration of the study – potentially 6 years. It also contained 
the longest follow-up for patients on any alpha-adrenergic 
receptor antagonist and demonstrated excellent safety and 
tolerability of tamsulosin. Alfuzosin, another uroselective 
agent, available in Europe for years, but recently approved 
by the FDA in the USA,29 results in improvement of LUTS 
and flow rates that appear sustainable over time.30
Patients on alpha-adrenergic receptor antagonist therapy 
need to be monitored for the development of side effects, 
particularly on initiation of therapy. The non-uroselective 
Table 1 Adverse events with alpha-adrenergic receptor antagonists (placebo rates in parenthesis)27,50
Terazosin (%) Alfuzosin OD (%) Doxazosin (%) Tamsulosin (%)
Dizziness 3–26 (3–7) 2.1–7.4 (1.3–2.9) 17–24 (4–6) 3–11 (0–5)
Hypotension 2–9 (0.5–1) 0.7–3.4 (0.0–3.4) 2.5–8.0 (0.0) 0.0 (0.5–1.0)
ejaculatory disorders 0.0–1.4 (0.0–1.0) 0.0–0.6 (0.0–1.3) 0.0 (0.0) 1.0–26.0 (0.0–1.0)
Discontinuations 16–38 (8–17) 11 (6) 11–22 (4–23) 7–13 (9–11)Patient Preference and Adherence 2009:3 216
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agents, terazosin and doxazosin, in particular need to be 
titrated to ensure that orthostatic hypotension does not 
develop.27
5-alpha-reductase inhibitors
The design and chemistry of 5-alpha-reductase inhibitors 
has been thoroughly studied and reviewed.31 The most 
extensively studied are the 17b-substituted-4-azasteroids of 
which two (finasteride and dutasteride) are now approved 
for human use. The first of these to be approved for use 
by the FDA for treatment of BPH was finasteride, a potent 
competitive inhibitor of 5-alpha-reductase that shows no 
affinity for the androgen receptor.32 This drug inhibits the 
type 2 isoenzyme of 5-alpha-reductase, which is present at 
high levels in the prostate. The principal North American 
study to evaluate efficacy was conducted by the Finasteride 
Study Group in 1992.33 This study of 895 men revealed 
a small but significant improvement in symptoms and flow 
rate with finasteride over placebo. The study also noted an 
approximately 20% decrease in prostate volume after 1 year 
of treatment with finasteride. These results were confirmed 
by a subsequent European study.34
The definitive muticenter trial to examine the role 
of finasteride in the treatment of symptomatic BPH was 
performed by the Finasteride Long-Term Efficacy and Safety 
Study group (PLESS) and was reported in 1998.3 This large 
double-blind, randomized, placebo-controlled trial studied 
3040 men with moderate-to-severe urinary symptoms and 
enlarged prostate glands who were treated with 5 mg of 
finasteride daily or placebo for 4 years. At the end of the 
study, patients treated with finasteride had a significantly 
higher decrease in AUASS (2.6 vs 1.0) and increase in 
Qmax (1.9 mL/sec vs 0.2 mL/sec) compared to placebo. 
The prostate volume also decreased an average 18% in the 
finasteride group compared to an increase of 14% in the 
placebo group. The most significant finding in the study, 
however, related to the progression of BPH. The group of 
men treated with finasteride had a significantly lower risk 
of acute urinary retention (51% risk reduction) and the need 
for BPH-related surgery (55% risk reduction). The benefit of 
finasteride was evident at 4 months and continued throughout 
the trial. Long-term (7- to 8-year) experience with finasteride 
has been reported and revealed that long-term treatment 
with finasteride was well tolerated and resulted in durable 
symptom relief and improvement in prostate volume and 
urinary flow.35
Subgroup analysis of the PLESS data revealed that men 
in the finasteride treated arm had significantly less bother, 
activity interference, and worry due to urinary symptoms than 
the placebo group, with more pronounced differences in men 
with PSA levels greater than 1.4 ng/mL.36 In fact, baseline 
serum PSA and prostate volume predicted long-term changes 
in symptoms and flow rate.17 Patients with baseline serum 
PSA levels greater than 1.4 ng/mL and enlarged prostates had 
the best response to finasteride versus placebo. Age was not 
a factor in the efficacy of finasteride.37 There was no impact 
on bone mineral density in men treated with finasteride.38 The 
Finasteride Urodynamics Study Group evaluated pressure-
flow parameters in men receiving finasteride for 2 years and 
found that men with prostate volumes greater than 40 mL 
continued to have decreases in detrusor pressure at Qmax 
throughout the course of the study.39
Dutasteride, a type 1 and type 2 5-alpha-reductase 
inhibitor, was approved for the treatment of BPH by the 
FDA in 2002. Dutasteride, because of dual inhibition of 
5-alpha-reductase, results in a greater than 90% decrease in 
serum DHT levels.40 Three parallel, multicenter, randomized, 
placebo-controlled trials of 24 months’ duration have 
examined the safety and efficacy of dutasteride in men with 
BPH.40 All three studies included men 50 years or older with 
a clinical diagnosis of BPH, a transrectal ultrasonography 
(TRUS) prostate volume greater than 30 mL, AUASS of 
12 or more, and Qmax of 15 mL/sec or less. The pooled 
results of these trials showed a significantly lower AUASS 
for the dutasteride arm versus placebo (-4.5 vs –2.3), and 
significantly higher Qmax for the dutasteride arm vs placebo 
(2.2 mL/sec vs 0.6 mL/sec) at 24 months. The prostate 
volume decreased by approximately 25% at 2 years. These 
studies also confirmed the PLESS finding of decreased BPH 
progression in patients being treated with 5-alpha-reductase 
inhibitors. Risk reduction of acute urinary retention was 
57% and the risk reduction of BPH-related surgery was 48% 
compared with placebo. These studies also evaluated the 
adverse events of dutasteride and found a small but signifi-
cant increase in impotence, decreased libido, gynecomastia, 
and ejaculation disorder. Interestingly, only the rate of 
gynecomastia was significantly higher than placebo after 
1 year of therapy. The PLESS trial noted similar adverse 
events with finasteride (Table 2).
Men started on 5-alpha-reductase inhibitor therapy 
should be counseled about the slow onset of action of 
this therapy (greater than 3 months) and about the side 
effects of the therapy. Table 2 lists the side effects, mainly 
sexual including decreased libido, impotence, ejaculatory 
disorder, and gynecomastia.33,40 A breast examination 
should be performed periodically by the physician and Patient Preference and Adherence 2009:3 217
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the patient because of the risk of gynecomastia. The side 
effects tend to diminish after a period of time, a fact that 
should be made clear to patients. Consideration should be 
given to a transrectal ultrasound guided systematic biopsy 
of the prostate to rule out significant prostate cancer in 
those men with elevated PSAs. The PSA decreases by 
about 50% after a year of therapy from baseline with 
5-alpha-reductase inhibitors – a fact that should be accounted 
for during yearly prostate cancer screening for men greater 
than age 50.40 A reasonable rule-of-thumb for men who are 
candidates for prostate cancer screening and who have been 
on 5-alpha-reductase inhibitor monotherapy or combination 
therapy is to use a PSA cutoff level of 2.0 ng/mL to initiate 
further diagnostic workup for prostate cancer.
5-alpha-reductase inhibitor therapy may also play a role in 
the treatment of BPH-induced hematuria and an adjunct role 
in the surgical treatment of BPH. Recent studies demonstrate 
that 5-alpha-reductase inhibitors are effective in the treatment 
of BPH-induced hematuria,41 probably through their effect 
on prostate microvessel density.42 Multiple studies now 
support the role of short-term 5-alpha-reductase inhibitor 
monotherapy prior to definitive surgical resection in order to 
decrease hematuria during and after the procedure.43,44
5-alpha-reductase inhibitor  
and alpha-adrenergic receptor  
antagonist combination therapy
The role of finasteride as monotherapy and as part of 
combination therapy with terazosin was examined in 
1996 by the Veterans Affairs Cooperative Studies Benign 
Prostatic Hyperplasia Study Group.45 This double-blind, 
placebo-controlled study enrolled 1229 men and studied 
the effects of placebo, finasteride alone, terazosin alone, 
and finasteride and terazosin on men with respect to AUASS 
and Qmax for 1 year. The AUASS decreased by more 
than 3 points in the terazosin and combination arm but did 
not significantly change in the finasteride group compared 
with placebo. Similarly, the Qmax increased significantly 
in the terazosin and combination arms (1.3 and 1.8 mL/sec) 
but did not change in the finasteride arm when compared 
to placebo. The results of this study did not agree with 
5-alpha-reductase inhibitor studies, perhaps because the 
average prostate size in the VA study was much smaller 
than in earlier trials.
Following the VA Cooperative study, a European 
study to evaluate the effect of combination therapy was 
undertaken. The PREDICT trial was a prospective, double-
blind, placebo control trial that randomized 1095 men aged 
50 to 80 years to treatment for 52 weeks with doxazosin, 
finasteride, the combination, and placebo.46 Doxazosin 
was titrated to a maximum of 8 mg per day to maximize 
symptomatic improvement or urinary flow rate improvements 
without the development of hypotension. Finasteride 
was administered at the standard 5 mg daily dose. The 
discontinuation rates for doxazosin (28%), finasteride (31%), 
and combination (31%) were similar to placebo (28%). 
This 1-year study showed a significant improvement in the 
doxazosin and combination groups compared to placebo 
with respect to AUASS (-8.3 and -8.5 vs -5.7) and Qmax 
(3.6 mL/sec and 3.8 mL/sec vs 1.4 mL/s). Interestingly, this 
study did not show a difference in the finasteride group com-
pared to placebo. This result was similar to and appeared to 
validate the results of the VA cooperative study. However, 
the limitations of the PREDICT trial are likely the same as 
that for the VA study – the average prostate size was small 
(36 mL) and the results were measured short term (1 year) 
compared to the PLESS and dutasteride monotherapy studies. 
The 4-year PLESS study and the 2-year dutasteride studies 
both showed significant improvements in AUASS and Qmax 
with 5-alpha-reductase monotherapy in contrast to the 1 year 
VA Cooperative and the PREDICT trial.
The definitive study for evaluation of combination 
therapy was sponsored by the National Institute of Health 
and initiated in 1995. The Medical Therapy of Prostate 
Symptoms (MTOPS) study was designed to evaluate 
the long-term efficacy of the alpha-adrenergic receptor 
antagonist doxazosin and the 5-alpha-reductase inhibitor 
finasteride, whether taken as monotherapy or in combination, 
in preventing or delaying the progression of BPH.47 MTOPS 
randomized 3047 men at least 50 years of age with moderate 
Table 2 Adverse events with 5-alpha-reductase inhibitors.33,40
Finasteride (%) Dutasteride (%) Placebo (%)
Asthenia 2 3
Dizziness 5   5
Gi symptoms 6   6
Headache 4   5
Hypotension 4   2
Nasal congestion 9   6
ejaculatory 
disorders
4 2 1
erectile 
dysfunction
8 7 4
Decreased libido 5 4 3
Gynecomastia 1 2 2
Notes: bold is significantly different from placebo p  0.05.Patient Preference and Adherence 2009:3 218
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to severe symptoms of BPH based on AUASS who had no 
previous medical, surgical, or experimental interventions for 
BPH into one of four groups: doxazosin alone, finasteride 
alone, placebo, and the combination of finasteride and 
doxazosin. BPH related events (four-point rise in AUASS, 
creatinine rise attributed to BPH, acute urinary reten-
tion, recurrent urinary tract infection or urosepsis, and 
incontinence), incidence of BPH invasive therapy, change in 
Qmax, and change in AUASS were measured in each group. 
Initial results of the MTOPS study were presented in 2002 
and the final results were published in 2004.4 At 5 years, 
the rate of acute urinary retention and invasive surgery was 
significantly higher in the doxazosin and placebo groups 
compared to the finasteride and combination groups. Changes 
in AUASS and Qmax were highest in the combination 
group at year 4 (3.0 and 2.3 mL/sec difference between 
combination and placebo). The doxazosin group had slightly 
higher changes in AUASS and Qmax than the finasteride 
group (2.0 and 1.1 mL/sec versus 1.0 and 0.8 mL/sec), but 
both were significantly better than placebo. The investigators 
went further and evaluated whether any baseline parameter 
predicted BPH progression. In their analysis, an AUASS 
greater than 17 predicted BPH progression and increased 
rate of BPH-related therapy in all groups. PSA greater than 
1.6 ng/mL predicted symptom and overall BPH progression 
in the doxazosin group, acute urinary retention in all groups, 
and BPH-related therapy in the doxazosin and combination 
groups but not in the finasteride group. A TRUS volume 
greater than 31 mL predicted acute urinary retention in the 
doxazosin and finasteride groups but not in the combination 
group. They concluded that baseline parameters are of 
most utility in predicting progression in the doxazosin 
group compared to the finasteride and combination groups. 
These results along with the PLESS results changed the 
paradigm for medical therapy. Two different goals of 
medical therapy are now apparent – treat the symptoms of 
BPH and prevent progression of BPH. Symptoms can be 
treated with alpha adrenergic receptor antagonists, long-term 
5-alpha-reductase inhibitor therapy, or combination therapy 
whereas only 5-alpha-reductase inhibitors (as mono-
therapy or part of combination therapy) seem to prevent 
progression of BPH.
In the early 21st century, 5-alpha-reductase therapy 
is used to prevent progression of BPH, and is a viable 
alternative to alpha blockers or combination therapy 
for the treatment of symptoms. Table 3 summarizes 
data from multiple clinical trials that evaluated use of 
5-alpha-reductase inhibitors as monotherapy or as part of 
combination therapy. The PLESS and MTOPS trials, along 
with recent data on dutasteride, clearly show that therapy 
with a 5-alpha-reductase inhibitor decreases the risk of acute 
urinary retention and BPH-related surgery.3,4,40 These trials 
also confirm that BPH progression is related to baseline 
PSA, with values greater than 1.4–1.6 ng/mL leading 
to significantly greater risk of BPH-related events.3,4 
Baseline prostate size has similar implications. Prostate 
volumes greater than 30 to 40 mL are also associated with 
significantly higher rates of BPH-related events.3,4 The 
improvement in AUASS and Qmax with 5-alpha-reductase 
inhibitors is significantly different from placebo.3,4,40 Open 
label extensions of early trials show that the results of 
finasteride are durable without increases in adverse events 
at 6 to 10 years.35,48,49 Prior to release of MTOPS data, 
alpha adrenergic receptor antagonists seemed to have 
a greater impact on improvement in Qmax and AUASS.24–26,50 
However, results of the MTOPS trial clearly show that the 
combination of alpha adrenergic receptor antagonists and 
5-alpha-reductase inhibitors has the greatest impact on Qmax 
Table 3 Summary of large North American studies that evaluated the role of 5-alpha-reductase inhibitor monotherapy and combination 
therapy with 5-alpha-reductase inhibitors and alpha-adrenergic receptor antagonists3,4,33,40,45
Finasteride 
study group
VA coop 
(5ARI)
VA coop 
(comb)
PLESS MTOPS 
(5ARI)
MTOPS 
(comb)
Dutasteride 
multicenter
Year published 1992 1996 1996 1998 2004 2004 2002
Follow-up (years) 1 1 1 4 5 5 2
Number of patients 895 243 254 1384 768 786 1510
Mean prostate volume 36.2 37.2 54 36.9 36.4 55
Change in AUASS decreased NS 3.6 2 1 3 2.2
Change in Qmax 1.6 NS 1.8 1.7 0.8 2.3 1.6
rr in AUr Nr Nr Nr 57 68 81 57
rr in BPH surgery Nr Nr Nr 55 64 67 48
Abbreviations: AUASS, American Urological Association’s Symptom Score; AUR, acute urinary retention; BPH, benign prostatic hyperplasia; NS, not significant; NR, not reported.Patient Preference and Adherence 2009:3 219
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and AUASS.4 Therefore, it is reasonable to use combination 
therapy on most men, and reserve 5-alpha-reductase 
monotherapy for those men that cannot tolerate alpha-
adrenergic receptor antagonists because of side effects, 
those that are unwilling to pay for two medications, or those 
men with large volume prostates or elevated PSA who are at 
a high risk of progression without LUTS. The MTOPS data 
demonstrates that the improvements in Qmax and AUASS 
achieved by 5-alpha-reductase inhibitor and alpha-adrenergic 
receptor antagonist combination therapy are significantly 
greater than either alone. If combination therapy cannot 
be tolerated, improvements by 5-alpha-reductase inhibitor 
monotherapy approach those that are achieved by alpha-
adrenergic receptor antagonist monotherapy, although the 
time to achieve these results is longer.
Anticholinergic therapy
Newer classes of pharmacologic agents have recently 
been used to treat LUTS secondary to BPH. LUTS due to 
BPH often coexists with LUTS due to overactive bladder 
(OAB), and the most common pharmacologic agents for 
the treatment of OAB symptoms are anticholinergics. This 
fact has led to multiple studies evaluating the efficacy of 
anticholinergics for the treatment of LUTS secondary to 
BPH. Tolterodine extended release was shown to be of 
benefit in men that could not tolerate alpha blockers. In a 
prospective trial of 43 patients, treatment with tolterodine 
extended release significantly reduced AUASS by 6.1 points 
6 months after initiation of therapy51 and also resulted in 
significant improvement in maximum flow rate and post-void 
residual urine. A subsequent randomized trial compared 
tolterodine ER, tamsulosin, placebo, and combination.52 
This study determined that tamsulosin alone and the 
combination of tamsulosin and tolterodine ER resulted 
in significant improvent in IPSS compared to the other 
two groups. However, with respect to IPSS QOL score, 
the combination of tamsulosin and tolterodine ER was 
significantly better than either drug alone or placebo. 
This may be due to patients that suffer from incontinence 
due to BPH and are not reliably captured by the IPSS, 
but are capture by the IPSS QOL score. Interestingly, 
despite a high rate of dry mouth (27% in the combination 
group), adverse events were low in all groups, and urinary 
retention only occurred in 0.7% of the patients treated with 
toterodine ER, alone or in combination. Anticholinergic 
agents may be a useful adjunt to alpha blocker therapy 
in patients that suffer from irritative symptoms53 or have 
small volume prostates.54
Phosphodiesterase inhibitors
Another class of medications that has shown improvement in 
LUTS secondary to BPH is phosphodiesterase-5 inhibitors, 
used currently in the treatment of erectile dysfunction. 
A recent study showed significant improvement in LUTS 
secondary to BPH in patients that received sildenafil and 
alfuzosin over patients that received alfuzosin alone.55 
All three of the PDE5 inhibitors available in the US, 
sildenafil,55 vardenafil,56 and tadalafil,57 appear to be effective 
in the treatment of LUTS secondary to BPH. The use of 
phosphodiesterase-5 inhibitors in not without controversy, 
however, given the fact that short-active phosphodiesterase 
inhibitors such as sildenafil need to dosed separate from 
alpha-blockers such as tamsulosin because of potential 
hypotensive effects.
Botulinum toxin A
Injection of botulinum toxin A into the prostate is a novel 
treatment for LUTS secondary to BPH. This treatment, 
applied through trans-perineal injection of 100 units of 
botulinum toxin into each lobe of the prostate under trans-
rectal guidance, was subjected to a randomized control 
trial, first reported in 2003.58 In this trial 30 patients showed 
significant improvement in IPSS (65% decrease) and serum 
PSA (51% decrease) compared to controls, who had injections 
of saline without botulinum toxin A, at a median follow-up of 
19.6 months. Subsequent long term follow-up of 77 patients 
up to 30 months has shown similar results – significant 
reduction in IPSS (approximately 50% lower), significant 
improvement in maximum flow rate (approximately 70% 
higher), and significant reduction in serum PSA values 
(approximately 50% lower).59 Importantly, no adverse events 
were noted.
Surgical therapy
Surgical therapy remains a mainstay for treatment of LUTS 
secondary to BPH, refractory to medical therapy. As noted 
earlier, there are a host of surgical procedures available. 
Current practice is to offer minimally invasive surgery to 
patients who do not want or are unfit for a more involved 
operation. Endoscopic surgery is the gold standard for 
treatment of LUTS secondary to BPH, with open surgery 
reserved for those patients with large glands or those that 
need concomitant procedures.
Minimally invasive surgery
Multiple BPH therapies, including water-based thermother-
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minimally invasive. Currently accepted forms of minimally 
invasive surgery are TUMT and TUNA. In the USA, FDA 
approved TUMT therapies are Thematrx TMX-2000™, 
Prostatron®, Targis®, Cooled ThermoCath®, CoreTherm®, and 
Prolieve®.60 TUMT is an office-based procedure that uses a 
catheter based system containing a microwave antenna for 
energy delivery. It has evolved from the original low-power 
to the current high-power treatments. In general, TUMT is 
considered safer than standard endoscopic therapies for LUTS 
secondary to BPH such as TURP, with lower rates of hematuria, 
urinary tract infection, erectile dysfunction, ejaculatory 
problems, urethral strictures, urinary incontinence, and blood 
transfusion. TUMT decreases IPSS by 24% to 87%, and 
increases maximum urinary flow rate by approximately 50%. 
While these results are better than medical therapy, TUMT is 
associated with rates of invasive retreatment as high as 66% 
at 5 years.61 In addition, TUMT therapy in contraindicated 
in patients with adverse anatomy (such as the presence of 
a significant prostatic intra-vesical component) and is not 
recommended for patients in urinary retention.
TUNA is an office-based therapy, first introduced in 
1993, that relies on delivering energy via a radiofrequency 
generator, an optical transurethral device and monopolar 
catheters that allow selective necrosis of tissue.62 Similar to 
TUMT, TUNA likewise is safer than TURP but with less 
efficacy. The only FDA approved TUNA system in the USA 
is ProstivaTM.
Endoscopic therapy
electrosurgical transurethral resection 
of the prostate
TURP is a transurethral endoscopic procedure that relies on 
electrosurgical resection of prostate adenoma, followed by 
removal of “prostate chips” from the bladder with an aqueous 
evacuator.63 It has been performed since early in the last 
century, and has evolved to be the procedure of choice for 
surgical treatment of LUTS secondary to BPH and is often 
called the gold standard surgical treatment for BPH/LUTS. 
While TURP is known to be efficacious for the treatment of 
LUTS secondary to BPH, it is associated with reasonably 
high rates of complications, including hematuria, reoperation, 
dilutional hyponatremia, and the need for blood transfusion.64 
Advances in optics and energy generation/delivery systems 
have decreased complications significantly in modern 
times.65 However, the number of TURPs performed in the 
USA continues to decrease yearly, perhaps because of the 
perception of increased morbidity.66
Transurethral electro-vaporization of the prostate 
evolved from the electrosurgical TURP to limit morbidity, 
particularly hematuria and blood transfusions.67 Subsequent 
meta-analysis has shown this modality to be comparative to 
TURP.68 Electrovaporization, however, does require higher 
energy sources and therefore has not been adopted by the 
general urology community.
Saline bipolar transurethral resection of the prostate is 
a further evolution of electrosurgical TURP.69 It consists of 
similar transurethral equipment as TURP; however, it relies on 
bipolar current with both electrodes within the cystoscope and 
therefore can be used with saline as the irrigant. This decreases 
the risk of dilutional hyponatremia and allows the operator to 
perform the procedure for a longer period of time. Multiple 
randomized control trials have shown similar efficacy to 
TURP.70 Some have touted this procedure as a useful adjunct 
to resident training because of the fact that saline is used as an 
irrigant decreasing the risk of dilutional hyponatremia – which 
increases with operative time in standard TURP.71
A limited version of the electrosurgical TURP is 
the TUIP, which is designed to limit rates of retrograde 
ejaculation, particularly for younger men interested in 
fertility. TUIP consists of deep unilateral or bilateral incisions 
through the base of the prostate from bladder neck to the 
veru montanum. A unilateral incision in on either side of 
midline (5 or 7 o’clock position as viewed through the 
cystoscope), whereas a bilateral incision is on both sides. 
TUIP is indicated for patients with small volume prostate 
glands (less than 30 mL), and those interested in preserving 
antegrade ejaculation. The risk of retrograde ejaculation is 
markedly diminished with a TUIP as compared to a TURP 
with rates around 20% for bilateral TUIP.72
Transurethral laser procedures
Laser procedures for LUTS secondary to BPH have been 
available since the mid 1990s. The neodymium-based visual 
laser ablation of the prostate procedure was a endoscopic 
procedure which relied on using a 980 nm neodymium 
laser which essentially cause coagulation necrosis of the 
underlying tissue.73 This procedure proved efficacious in 
the long term, but had significant short-term morbidity, 
particularly retreatment or urinary retention with the need for 
a urethral catheter for a prolonged period of time.74 Because 
of the significant short term urinary morbidity and the advent 
of more efficacious laser procedures, this procedure has been 
generally abandoned by practicing urologists.
Two other laser technologies based on the Holmium laser 
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of symptomatic BPH. The holmium laser was first used for 
LUTS secondary to BPH as an ablative procedure, also known 
as Holmium laser ablation of the prostate (HoLAP).75 This 
procedure consists of visually ablating prostate tissue with 
a 1032 nm Holmium laser using a near-contact technique. 
HoLAP is efficacious as compared to TURP with reasonable 
long-term results, decreased morbidity, but at the cost of 
higher operative times.76 Holmium laser enucleation of the 
prostate (HoLEP) is a procedure which consists of using an 
end-firing fiber to aim the holmium laser beam at the interface 
between the surgical capsule and the prostate adenoma and 
enucleating the prostate adenoma by separating it from the 
peripheral zone.77 This technique is somewhat difficult to 
master, but once mastered results are excellent.78 In fact, its 
efficacy is comparable to open prostatectomy in large glands 
and TURP in smaller glands with decreased morbidity.79
The Greenlight laser vaporization of the prostate is the 
newest laser procedure for treatment of LUTS secondary 
to BPH. It consists of using a 532 nm potassium tytanyl 
phosphate/greenlight laser in non-contact mode to ablate 
prostate tissue.80 Greenlight laser vaporization of the prostate 
has been shown to be as effective as TURP with decreased 
morbidity in a host of patient populations.81,82 Because it is 
extremely hemostatic and uses saline as the irrigant, there is very 
little risk of significant bleeding or dilutional hyponatremia, 
making this modality ideal for high-risk patients.83,84 Laser 
procedures for the prostate have increased dramatically since 
the widespread adoption of the high-power Greenlight laser 
vaporization of the prostate around 2002, and now account for 
approximately 30% of surgical procedures for BPH.85
Open prostatectomy
Open (or “simple”) prostatectomy is an open surgical 
procedure that consists of enucleating the prostate adenoma 
through a transvesical, suprapubic route or a trans-prostate, 
retropubic route.86 This operation is the most efficacious for 
patients with large volume prostate glands. However, it is 
associated with significant blood loss, prolonged hospital 
stay, and increased morbidity as compared to TURP or laser 
procedures. Typically, in the age of advanced endoscopic 
surgery, open prostatectomy is reserved for patients fit for 
open surgery with large volume glands and the need for 
concomitant procedures, such as removal of large bladder 
stones or the need for a bladder diverticulectomy.
Conclusion
Theraputic options for treatment of LUTS secondary to BPH 
are varied. Once other causes of LUTS have been eliminated, 
it is reasonable to treat mild to moderate LUTS with medical 
therapy. Initial medical therapy consists of alpha blockers, 
5-alpha-reductase inhibitors, or a combination. Additional 
classes of pharmacologic agents appear to have efficacy for 
LUTS, including anti-cholinergic agents and phosphodiesterase 
inhibitors, and may be included in the pharmacologic arma-
mentarium in the future, but are not as of yet considered 
standard of care. Surgical therapy is an option for patients that 
are unable to tolerate medical therapy or for whom medical 
therapy is not efficacious. Traditional surgical therapy consists 
of TURP, which is still considered the gold standard. Laser 
procedures, particularly Greenlight laser vaporization of the 
prostate or Holmium laser ablation/enucleation of the prostate, 
are being used more often with similar results as TURP and 
decreased complications. Open surgery for LUTS secondary 
to BPH is reserved for patients with very large symptomatic 
prostate glands or those with concomitant pathology such as 
large bladder stones or symptomatic bladder diverticula.
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